Preeclampsia is a hypertensive disorder that occurs during pregnancy characterized by high blood pressure and signs of damage to another organ system. Diagnosis of preeclampsia typically involves measuring blood pressure and testing urine for protein. Early detection of preeclampsia is crucial for the management of the condition as it enables timely treatment and close monitoring to prevent progression to severe preeclampsia. Point of care (POC) diagnostic devices play a crucial role in early detection of the condition. These devices can detect the presence of key biomarkers like placental growth factor (PlGF) to diagnose preeclampsia at an early stage. Growing awareness about the importance of early diagnosis and management of preeclampsia is driving the adoption of POC diagnostic devices for preeclampsia screening. The global preeclampsia diagnostics market is estimated to be valued at US$ 1587.53 Mn in 2023 and is expected to exhibit a CAGR of 4.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
Early diagnosis of preeclampsia through screening programs and increased awareness are expected to drive the growth of the global preeclampsia diagnostics market over the forecast period. Growing incidences of preterm births associated with preeclampsia is also fueling the adoption of screening and diagnostic tests. According to WHO, preterm birth complications are the leading cause of death among children under 5 years of age, resulting in around 1 million deaths in 2015. Increased focus on curbing preterm births through effective preeclampsia management will create opportunities for POC diagnostic device manufacturers in coming years. However, limited accessibility of diagnostic facilities in low-income countries continues to hinders the market growth. Key players are collaborating with governments and NGOs to expand diagnostic coverage in underserved regions, which can help address this challenge to some extent over the forecast period.
Segment Analysis
The global preeclampsia diagnostics market is dominated by the blood tests segment which holds around 60% of the total market share. Blood tests are the most common and widely used diagnostics method for detecting preeclampsia as it allows to easily measure biomarkers like placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) in the blood which are altered in preeclampsia conditions. Moreover, blood tests are minimally invasive, cost-effective and easy to perform, which has led to its increased adoption rate compared to other segments.
PEST Analysis
Political: Governments across various countries are focusing on improving maternal and child care facilities. Favorable regulations and reimbursement policies related to preeclampsia diagnostics are expected to support the market growth.
Economic: Rising incidence of preterm births and preeclampsia cases globally is increasing the healthcare burden. This is encouraging investments in the development of advanced and affordable diagnostic solutions.
Social: Growing awareness about the health risks associated with preeclampsia to both mother and child is positively impacting the demand for early diagnostic tests.
Technological: Players are focusing on developing novel diagnostic markers and enhancing existing product capabilities using AI, bioinformatics and portable devices for improved accuracy and widespread accessibility.
Key Takeaways
The Global Preeclampsia Diagnostics Market Size is expected to witness high growth at a CAGR of 4.5% during the forecast period of 2023 to 2030.
Regional analysis: The North America region is expected to retain its leading position during the forecast period driven by factors such as rising maternal age, growing obesity rates and technological advancements. The APAC market is projected to witness fastest growth at a CAGR of around 6% owing to improving healthcare infrastructure, increasing chronic disease burden and growing medical tourism in countries like India and China.
Key players operating in the preeclampsia diagnostics market are The Dow Chemical Company, BASF SE, Covestro A.G., Huntsman Corp., Eastman Chemical Co., Mitsui Chemicals Inc, Recticel S.A., RTP Company Inc., Lubrizol Corp., and Rampf Holding GmbH & Co. KG. Major players are focusing on new product launches, collaborations and geographic expansions to strengthen their market presence.
*Note:
1.Source: Coherent Market Insights, Public sources, Desk research
2.We have leveraged AI tools to mine information and compile it
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. With an MBA in E-commerce, she has an expertise in SEO-optimized content that resonates with industry professionals.